Effect of vitamin E supplementation on HDL function by haptoglobin genotype in type 1 diabetes: results from the HapE randomized crossover pilot trial.

Item request has been placed!

Item request cannot be made.

Processing Request

Read More Add to Saved list

Author(s): Costacou T;Costacou T; Levy AP; Levy AP; Miller RG; Miller RG; Snell-Bergeon J; Snell-Bergeon J; Asleh R; Asleh R; Farbstein D; Farbstein D; Fickley CE; Fickley CE; Pambianco G; Pambianco G; de la Vega R; de la Vega R; Evans RW; Evans RW; Orchard TJ; Orchard TJ
Source:
Acta diabetologica [Acta Diabetol] 2016 Apr; Vol. 53 (2), pp. 243-50. Date of Electronic Publication: 2015 May 24.
Publication Type:
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Language:
English

Additional Information
- Source:
  Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9200299 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-5233 (Electronic) Linking ISSN: 09405429 NLM ISO Abbreviation: Acta Diabetol Subsets: MEDLINE
- Publication Information:
  Publication: Berlin : Springer Verlag
  Original Publication: Berlin : Springer International, c1991-
- Subject Terms:
  Diabetes Mellitus, Type 1/*genetics ; Haptoglobins/*genetics ; Lipoproteins, HDL/*metabolism ; Vitamin E/*therapeutic use ; Vitamins/*therapeutic use; Adult ; Aged ; Alleles ; Cohort Studies ; Cross-Over Studies ; Diabetes Mellitus, Type 1/therapy ; Dietary Supplements ; Double-Blind Method ; Female ; Genotype ; Humans ; Lipid Peroxidation/drug effects ; Lipoproteins, LDL/blood ; Lipoproteins, LDL/metabolism ; Male ; Middle Aged
- Abstract:
  Aims: Haptoglobin (Hp) genotype 2-2 increases cardiovascular diabetes complications. In type 2 diabetes, α-tocopherol was shown to lower cardiovascular risk in Hp 2-2, potentially through HDL function improvements. Similar type 1 diabetes data are lacking. We conducted a randomized crossover pilot of α-tocopherol supplementation on HDL function [i.e., cholesterol efflux (CE) and HDL-associated lipid peroxides (LP)] and lipoprotein subfractions in type 1 diabetes.
  Methods: Hp genotype was assessed in members of two Allegheny County, PA, type 1 diabetes registries and the CACTI cohort; 30 were randomly selected within Hp genotype, and 28 Hp 1-1, 31 Hp 2-1 and 30 Hp 2-2 were allocated to daily α-tocopherol or placebo for 8 weeks with a 4-week washout.
  Results: Baseline CE decreased with the number of Hp 2 alleles (p-trend = 0.003). There were no differences in LP or lipoprotein subfractions. In intention-to-treat analysis stratified by Hp, α-tocopherol increased CE in Hp 2-2 (β = 0.79, p = 0.03) and LP in Hp 1 allele carriers (β Hp 1-1 = 0.18, p = 0.05; β Hp 2-1 = 0.21, p = 0.07); reduced HDL particle size (β = -0.07, p = 0.03) in Hp 1-1 carriers; increased LDL particle concentration in Hp 1-1; and decreased it in Hp 2-2 carriers. However, no significant interactions were observed by Hp.
  Conclusions: In this type 1 diabetes study, HDL function worsened with the number of Hp 2 alleles. α-Tocopherol improved HDL function in Hp 2-2 carriers and appeared to adversely affect lipid peroxides and lipoprotein subfractions among Hp 1 allele carriers. As no significant interactions were observed, findings require replication in larger studies.
- References:
  Nature. 2004 May 27;429(6990):464-8. (PMID: 15164072)
  Diabetes Care. 2004 Nov;27(11):2767. (PMID: 15505023)
  Diabetes. 1981 Apr;30(4):279-84. (PMID: 7202862)
  Adv Hum Genet. 1982;12:189-261, 453-4. (PMID: 6751044)
  J Chromatogr. 1982 Sep 10;231(2):439-44. (PMID: 7130321)
  Anal Biochem. 1984 May 1;138(2):340-5. (PMID: 6742412)
  Free Radic Biol Med. 1988;5(2):113-24. (PMID: 3075947)
  Endocrinol Metab Clin North Am. 1990 Jun;19(2):361-80. (PMID: 2192878)
  Diabetes. 1990 Sep;39(9):1116-24. (PMID: 2384191)
  Diabetes. 1999 Jan;48(1):1-9. (PMID: 9892215)
  Atherosclerosis. 2005 Mar;179(1):69-77. (PMID: 15721011)
  Circ Res. 2005 Mar 4;96(4):435-41. (PMID: 15662028)
  Diabetes. 2005 Sep;54(9):2802-6. (PMID: 16123372)
  Clin Lab Med. 2006 Dec;26(4):847-70. (PMID: 17110242)
  Circ Res. 2006 Dec 8;99(12):1419-25. (PMID: 17082477)
  J Clin Invest. 2007 Mar;117(3):746-56. (PMID: 17332893)
  Arterioscler Thromb Vasc Biol. 2008 Feb;28(2):341-7. (PMID: 18032779)
  Diabetes. 2008 Jun;57(6):1702-6. (PMID: 18332093)
  Diabetes. 2008 Oct;57(10):2794-800. (PMID: 18599520)
  Atherosclerosis. 2010 Jul;211(1):25-7. (PMID: 20223458)
  N Engl J Med. 2011 Jan 13;364(2):127-35. (PMID: 21226578)
  J Cell Biol. 2011 Jul 11;194(1):7-15. (PMID: 21746850)
  Atherosclerosis. 2011 Nov;219(1):240-4. (PMID: 21722898)
  Cardiovasc Diabetol. 2011;10:99. (PMID: 22098782)
  Mol Cell. 2012 Oct 26;48(2):158-67. (PMID: 23102266)
  Arterioscler Thromb Vasc Biol. 2013 Jul;33(7):1696-705. (PMID: 23520163)
  Clin Chem Lab Med. 2013 Aug;51(8):1615-22. (PMID: 23492570)
  J Lipid Res. 2013 Sep;54(9):2307-14. (PMID: 23505320)
  Diabetes. 2013 Sep;62(9):3218-23. (PMID: 23761102)
  N Engl J Med. 2000 Sep 28;343(13):969-70. (PMID: 11012324)
  J Lab Clin Med. 2000 Jul;136(1):58-65. (PMID: 10882228)
  J Am Coll Cardiol. 2013 Nov 12;62(20):1909-10. (PMID: 23933538)
  J Am Coll Cardiol. 2002 Dec 4;40(11):1984-90. (PMID: 12475459)
  Lancet. 2003 Jun 14;361(9374):2017-23. (PMID: 12814711)
  Diabetes Care. 2003 Sep;26(9):2628-31. (PMID: 12941730)
  Diabetes. 2003 Nov;52(11):2833-9. (PMID: 14578303)
  Biochemistry. 2004 Apr 6;43(13):3899-906. (PMID: 15049697)
- Grant Information:
  R01 HL113029 United States HL NHLBI NIH HHS; UL1 TR000005 United States TR NCATS NIH HHS
- Contributed Indexing:
  Keywords: Double-blinded placebo-controlled randomized trial; HDL function; Haptoglobin genotype; NMR lipoprotein subfractions; Type 1 diabetes; Vitamin E
- Accession Number:
  0 (Haptoglobins)
  0 (Lipoproteins, HDL)
  0 (Lipoproteins, LDL)
  0 (Vitamins)
  1406-18-4 (Vitamin E)
- Publication Date:
  Date Created: 20150524 Date Completed: 20161213 Latest Revision: 20181202
- Publication Date:
  20221216
- Accession Number:
  PMC4826317
- Accession Number:
  10.1007/s00592-015-0770-8
- Accession Number:
  26002590

Comments

No Comments.